



Astec LifeSciences Ltd.

Dated: 10th November, 2015

To,
The Secretary
The Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
Manager-Listing
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051,

Ref.: BSE Scrip Code No. “533138”

Ref: “ASTEC”

Sub: Corrigendum to the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended 30th September, 2015 submitted to the Stock Exchange(s) on 6th November, 2015 .

Dear Sir,

With respect to the captioned subject, we would like to inform you that in the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended 30th September, 2015 which were submitted to Stock Exchange(s) on 6th November, 2015, certain items/figures (as stated below) were wrongly reported due to typographical errors.

The revised items/figures are given below:

Sr No	Particulars	Figures in Rupees/ Rupees in lacs	Segment	Period	Earlier reported Figures	Corrected Figures
1 (b)	Other Operating Income	Rs. in lacs	Standalone	Quarter ended 30 th September, 2014	(48.77)	28.24
2 (e)	Other Expenditure	Rs. in lacs	Standalone	Quarter ended 30 th September, 2014	248.16	325.17
1 (b)	Other Operating Income	Rs. in lacs	Standalone	Half Year ended 30 th September, 2014	47.01	75.83
2 (e)	Other Expenditure	Rs. in lacs	Standalone	Half Year ended 30 th September, 2014	508.38	585.39
5 (a)	Foreign Exchange Fluctuation (Profit)/Loss	Rs. in lacs	Standalone	Half Year ended 30 th September, 2014	77.01	28.82
2 (e)	Other Expenditure	Rs. in lacs	Standalone	Year ended 31 st March, 2015	1,510.00	1,511.00
16	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	Rs. in lacs	Consolidated	Quarter ended 30 th September, 2015	11,764.79	11,757.15
16	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	Rs. in lacs	Consolidated	Half Year ended 30 th September, 2015	11,764.79	11,757.15



Regd. Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone : +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecsl.com
Website : www.astecsl.com
CIN : L99999MH1994PLC076236



ASTECL

Astec LifeSciences Ltd.

1 (b)	Other Operating Income	Rs. in lacs	Consolidated	Quarter ended 30 th September, 2014	(68.19)	8.82
5 (a)	Foreign Exchange Fluctuation (Profit)/Loss	Rs. in lacs	Consolidated	Quarter ended 30 th September, 2014	-	77.01
1 (b)	Other Operating Income	Rs. in lacs	Consolidated	Half Year ended 30 th September, 2014	27.88	56.70
5 (a)	Foreign Exchange Fluctuation (Profit)/Loss	Rs. in lacs	Consolidated	Half Year ended 30 th September, 2015	196.24	244.28
5 (a)	Foreign Exchange Fluctuation (Profit)/Loss	Rs. in lacs	Consolidated	Half Year ended 30 th September, 2014	-	28.82
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (12-13-14)	Rs. in lacs	Consolidated	Half Year ended 30 th September, 2015	613.46	169.02
17	Earnings per share (Before Exceptional & Prior period items) - Basic & Diluted	In Rupees	Consolidated	Year Ended 31 st March 2015	6.73	13.56

We are also enclosing herewith revised Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2015.

The Revised Unaudited Financial Results for the quarter and half year ended 30th September, 2015 will also be published on 14th November, 2015 ie Saturday in Newspapers (Business Standard and Mumbai Lakshdeep).

Please take the above on your records.

Thanking you,
Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED

Tejal Jariwala
Company Secretary & Compliance Officer
ACS-32p441



Encl: A/a



Regd. Office :
Elite Square, 7th Floor,
274, Pe'in Nariman Street,
Fort, Mumbai - 400001, India
Phone: +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : info@astecls.com
Website : www.astecls.com
CIN : L99999MH1994PLC076236



ASTEC Lifesciences LTD

CIN No : L59999MH1994PLC076236

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai - 400001.

Website: www.astecsl.com, Tel no.022-61205600, Fax- 022-22618289, Email id: info@astecsl.com

Unaudited Financial Results for the quarter ended 30th Sept, 2015

PART I	STANDALONE						CONSOLIDATED						
	Rs. In Lacs (Except for per share data)						Rs. In Lacs (Except for per share data)						
	Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended	
	30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015	30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income from Operations												
	a) Net Sales / Income from operations (Net of Excise Duty)	6168.03	5442.24	5,908.67	11610.27	10,800.22	25120.68	7,123.29	5,722.58	6,635.24	12,845.87	11,728.10	26,652.11
	b) Other Operating Income	106.65	69.89	28.24	176.55	75.83	225.13	116.50	37.18	8.82	153.68	56.70	129.47
	Total Income from Operations (net)	6,274.69	5,512.13	5,936.91	11,786.82	10,876.05	25,345.82	7,239.79	5,759.77	6,644.06	12,999.55	11,784.80	26,781.58
2	Expenses												
	a) Cost of materials consumed Including Utilities	3906.41	4245.62	4,399.58	8152.03	7,753.37	16981.87	5,455.75	4,899.14	4,978.29	10,354.89	8,617.08	18,183.33
	b) Changes in inventories of finished goods and work in progress	177.59	(467.94)	(571.29)	(290.35)	(363.80)	241.20	(805.82)	(970.75)	(658.71)	(1776.57)	(616.61)	72.40
	c) Employee benefits expenses	306.10	273.07	252.56	579.17	494.42	1,143.93	363.30	324.43	309.73	687.72	592.19	1,244.00
	d) Depreciation and amortisation expenses	314.72	312.22	385.45	626.93	759.17	1,199.81	336.43	329.44	391.74	665.87	771.47	1,268.73
	e) Other expenditure	464.74	343.24	325.17	807.98	585.39	1,511.00	755.46	400.76	415.46	1,156.22	742.34	1,661.99
	Total Expenses	5,169.55	4,706.21	4,791.47	9,875.76	9,228.56	21,077.80	6,105.11	4,983.02	5,436.51	11,088.13	10,106.47	22,430.46
3	Profit/ (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	1,105.13	805.92	1,145.45	1,911.05	1,647.49	4,268.02	1,134.67	776.75	1,207.55	1,911.42	1,678.33	4,351.12
4	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	1,105.13	805.92	1,145.45	1,911.05	1,647.49	4,268.02	1,134.67	776.75	1,207.55	1,911.42	1,678.33	4,351.12
5	Finance Costs	319.60	283.04	300.82	602.65	537.15	1,210.09	340.34	296.49	335.29	636.83	601.06	1,284.00
5A	Foreign Exchange Fluctuation (Profit) / Loss	196.24	48.04	77.01	244.28	28.82	115.31	196.24	48.04	77.01	244.28	28.82	115.31
6	Profit after finance costs but before Exceptional Items (5-6)	589.28	474.84	767.61	1,064.12	1,081.52	2,942.62	598.09	432.22	795.25	1,030.31	1,048.45	2,951.82
7	Exceptional Items	922.86	114.69	-	1037.55	-	1,693.83	922.86	114.69	-	1,037.55	-	1,693.83
8	Profit / (Loss) from ordinary activities before tax	(333.58)	360.14	767.61	26.57	1,081.52	1,248.79	(324.77)	317.53	795.25	(7.25)	1,048.45	1,257.99
9	Tax Expense	(84.61)	132.30	160.66	47.69	231.66	410.98	(84.15)	132.70	161.90	48.55	233.06	419.35
10	Net Profit / (Loss) from ordinary activities after tax (8-9)	(248.97)	227.85	606.95	(21.12)	849.86	837.80	(240.62)	184.83	633.35	(55.80)	813.39	838.64
11	Extra ordinary / Prior Period Items	(137.72)	(84.10)	19.64	(221.83)	21.11	(639.62)	(137.72)	(84.10)	19.64	(221.83)	21.11	(639.62)
12	Net Profit / (Loss) for the period (10 - 11)	(111.25)	311.95	587.31	200.70	828.75	1,477.43	(102.90)	268.93	613.71	169.03	794.28	1,478.26
13	Minority Interest	-	-	-	-	-	-	(3.31)	0.32	0.24	(2.99)	0.41	0.72
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (12-13-14)	(111.25)	311.95	587.31	200.70	828.75	1,477.43	(99.59)	268.61	613.47	169.02	793.87	1,477.54
15	Paid-up equity share capital (Face Value Rs.10/-)	1,945.51	1,945.51	1,852.91	1,852.91	1,852.91	1,945.51	1,945.51	1,945.51	1,852.91	1,945.51	1,852.91	1,945.51
16	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	11,906.34	12,017.59	10,442.53	10,643.23	10,442.53	11,705.64	11,757.15	11,856.74	10,289.86	11,757.15	10,289.86	11,588.13
17	Earnings per share (Before Exceptional & Prior period items) - Basic & Diluted	3.46	1.76	3.28	5.22	4.59	13.55	3.51	1.54	3.42	5.05	4.28	13.56
18	Earnings per share (After Exceptional & Prior period items) - Basic & Diluted	(0.57)	1.60	3.17	1.03	4.47	7.91	(0.51)	1.38	3.31	0.87	4.40	7.91

PART II													
A	PARTICULARS OF SHAREHOLDING												
1	Public shareholding												
	- No of shares	8,698,075	8,698,075	7,772,150	8,698,075	7,772,150	8,698,075	8,698,075	8,698,075	7,772,150	8,698,075	7,772,150	8,698,075
	- Percentage of shareholding	44.71%	44.71%	41.95%	44.71%	41.95%	44.71%	44.71%	44.71%	41.95%	44.71%	41.95%	44.71%
2	Promoters and promoter group shareholding												
	a) Pledged / Encumbered												
	- No of shares	1,813,055	5,836,581	1,695,000	1,813,055	1,695,000	3,660,152	1,813,055	5,836,581	1,695,000	1,813,055	1,695,000	3,660,152
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	16.85%	54.26%	15.76%	16.85%	15.76%	34.03%	16.85%	54.26%	15.76%	16.85%	15.76%	34.03%
	- Percentage of shares (as a % of the total share capital of the company)	9.32%	30.00%	9.15%	9.32%	9.15%	18.81%	9.32%	30.00%	9.15%	9.32%	9.15%	18.81%
	b) Non-encumbered												
	- No of shares	8,943,925	4,920,399	9,061,980	8,943,925	9,061,980	7,096,828	8,943,925	4,920,399	9,061,980	8,943,925	9,061,980	7,096,828
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	83.15%	45.74%	84.00%	83.15%	84.00%	65.97%	83.15%	45.74%	84.00%	83.15%	84.00%	65.97%
	- Percentage of shares (as a % of the total share capital of the company)	45.97%	25.29%	49.00%	45.97%	49.00%	36.38%	45.97%	25.29%	49.00%	45.97%	49.00%	36.38%
	PARTICULARS												
B	INVESTOR COMPLAINTS												
	Pending at the beginning of the quarter	0	0	0									
	Received during the quarter	7	2	0									
	Disposed of during the quarter	5	2	0									
	Remaining unresolved at the end of the quarter	2	0	0									

Notes:

- The above unaudited financials results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 06.11.2015.
- The above financial results have been subject to limited review by Statutory Auditor.
- Above Financials include financial results of Behram Chemicals Pvt. Ltd. (65.63% subsidiary), Astec CropCare Pvt Ltd (100% Subsidiary of Astec) and Astec Europe Sprl (50.10% subsidiary). The Financial Results of Comercializadora Agricola Agrostrachem Cia Ltda at Columbia (100% Subsidiary of Astec) are not included as the company has not commercialised its operation.
- Financials of Astec Europe Sprl for the period ended 30th September 2015 has not been consolidated in the financial statements, as the required information was not available. Further, we confirm that there is no material impact on the financials. However, audited financials till 31st December 2014 has been consolidated for the said entity.
- The company has only one reportable segment i.e. Agrochemicals.
- Figures of the previous year have been regrouped/rearranged, wherever necessary.
- Promoters of Astec and Godrej Agrovet Ltd (GAVL) have entered into Share Purchase Agreement dated 28th August 15 for transfer of 45.29% equity shares to GAVL.
- Exceptional items of Rs.92,286,284 consists Provision for non receivable Government Dues of Rs.28,068,164, Capital Work in Progress written-off of Rs.33,316,153 and Provision for Doubtful Debts of Rs.30,901,967.
- Prior Period items consists income of MAT Credit Receivable of Rs.6,955,779, Export incentive of Rs.8,154,248 and payment of statutory liabilities of Rs.1,337,828
- Key standalone financial information of the company is given below :-

Particulars	Quarter Ended			Half Year Ended		Year ended
	30/09/2015	30/06/2015	31/03/2015	30/09/2015	30/09/2014	31/03/2015
	(Un Audited)	(Un Audited)	(Audited)	(Un Audited)	(Un Audited)	(Audited)
Net Sales / Income from operations (Net of Excise Duty)	6,168.03	5,442.24	5,908.67	11,610.27	10,800.22	25,120.68
Other Operating Income	106.65	69.89	28.24	176.55	75.83	225.13
Profit / (Loss) from ordinary activities before tax	589.28	474.84	767.61	1,064.12	1,081.52	2,942.62
Net Profit Profit / (Loss) from ordinary activities after tax	(248.97)	227.85	606.95	(21.12)	849.86	837.80
Earnings per share (Before Extra-ordinary & Prior period items) - Basic & Diluted	3.46	1.76	3.28	5.22	4.59	13.55
Earnings per share (After Extra-ordinary & Prior period items) - Basic & Diluted	(0.57)	1.60	3.17	1.03	4.47	7.91

For Astec LifeSciences Limited

Sd/
(Ashok V Hiremath)
Managing Director
Friday, 06 th November, 2015